Company intelligence / Profile preview

Silk Technologies, Ltd. (SILKTECH)

Plymouth, Minnesota, United Statessilktears.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has developed SILKTEARS, an OTC eye drop that provides lasting eye relief while improving tear quality. Their lead drug candidate SDP-4 has shown potent anti-inflammatory activity targeting known causes of Dry Eye Disease in pre-clinical studies, with enhanced wetting properties without increased viscosity[4][5].

Therapeutic areas: DermatologyOphthalmology
Modalities: Protein-based therapeutics
Industry: Biotech

Drug pipeline

1 asset

silktears

Commercial

Indications: Dry eye disease

Beyond the preview

Go deeper on Silk Technologies, Ltd. (SILKTECH).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silk Technologies, Ltd. (SILKTECH).

Explore the full profile